Nektar Therapeutics (NASDAQ:NKTR) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, NKTR is expected to report 3Q20 loss of $ 0.74 per share from revenue of $ 26.33 million.
For the full year, analysts anticipate top line of $ 147.90 million, while looking forward to loss of $ 2.84 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 140.00 million ~ $ 145.00 million
Click Here For More Historical Outlooks Of Nektar Therapeutics
Previous Quarter Performance
Nektar Therapeutics recorded loss for the second quarter of $ 0.45 per share, from the revenue of $ 48.85 million. The quarterly revenues elevated 109.48 percent compared with the same quarter last year. According to street consensus, NKTR was expected to report 2Q20 loss of $ 0.68 per share from revenue of $ 22.80 million. The bottom line results beat street analysts by $ 0.23 or 33.82 percent, at the same time, top line results outshined analysts by $ 26.05 million or 114.25 percent.
Stock Performance
Shares of Nektar Therapeutics traded up $ 1.20 or 7.61 percent on Wednesday, reaching $ 16.97 with volume of 1.06 million shares. Nektar Therapeutics has traded high as $ 17.26 and has cracked $ 15.85 on the downward trend
The closing price of $ 16.97, representing a 15.70 % increase from the 52 week low of $ 13.63 and a 44.86 % decrease over the 52 week high of $ 28.60.
The company has a market capital of $ 3.04 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Nektar Therapeutics will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.nektar.com
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology.
